GlaxoSmithKline Biologicals Gains FDA Approval Action on BOOSTRIX in May 2026

A May 14, 2026 FDA approval letter for GlaxoSmithKline Biologicals' BOOSTRIX marks the latest regulatory action on STN BL 125106, adding to a sequence of approval letters that stretches back to 2019 and signals continued post-market activity on this adsorbed Tdap vaccine. For QA directors and regulatory affairs leads managing biologics portfolios, a recurring approval cadence of this kind typically reflects label revisions, post-market commitment fulfillments, or manufacturing supplement approvals rather than a new product launch.

BOOSTRIX (Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine, Adsorbed) carries two approved indications under 21 CFR Part 601: active booster immunization against tetanus, diphtheria, and pertussis in individuals aged 10 years and older, and immunization during the third trimester of pregnancy to prevent pertussis in infants younger than two months of age. The maternal immunization indication, added in a prior cycle, places particular demands on labeling precision and pharmacovigilance infrastructure given the vulnerable infant population it is designed to protect.

The approval history for BOOSTRIX is notably dense. Letters issued in October and November 2022, followed by actions in June and October 2023, suggest an active supplemental BLA pipeline. Each approval letter in this sequence may carry distinct manufacturing, labeling, or post-market study obligations that plant heads and quality systems teams must track against their internal CAPA and change-control frameworks aligned with ICH Q10 pharmaceutical quality system principles.

The FDA's public-facing record includes a statistical review and a clinical review memo dated October 7, 2022, both of which remain accessible as supporting documents. These materials provide the evidentiary basis for at least one prior approval cycle and may inform how GSK Biologicals structures its responses to any outstanding post-market commitments tied to the maternal immunization indication.

The full package insert, updated to reflect the current approved labeling, is the primary reference document for any manufacturing or quality change that could affect product presentation, storage conditions, or administration guidance for this adsorbed vaccine.

The May 2026 letter's specific scope, whether it addresses a labeling supplement, a manufacturing site change, or a post-market study completion, will become clearer once the approval letter text is reviewed against the existing BLA docket, a step that regulatory affairs teams with active BOOSTRIX distribution responsibilities should prioritize before the next inspection cycle.

Source: U.S. Food and Drug Administration, Vaccines, Blood and Biologics / What's New RSS Feed, May 15, 2026.